IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Moderate Buy” by Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been given a consensus rating of “Moderate Buy” by the twenty-one ratings firms that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $249.05.

IQV has been the topic of several research reports. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Truist Financial reaffirmed a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently modified their holdings of IQV. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the 4th quarter worth approximately $44,000. Finally, Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV opened at $185.40 on Monday. The firm has a market capitalization of $32.69 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business’s fifty day moving average price is $196.63 and its 200 day moving average price is $210.43. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA has a 12 month low of $179.28 and a 12 month high of $256.34.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.